Wegovy’s one-third price slash in India aims to outdo rival Mounjaro, now the top-selling medicine by value. Danish pharma Novo Nordisk has reduced the weekly cost of its obesity drug from Rs 4,336 to Rs 2,712 for its injectable version containing semaglutide. The new prices are part of a strategy to make Wegovy more accessible to people with obesity and overweight in India. With Mounjaro already dominating sales, Novo Nordisk is seeking to regain ground by offering an affordable alternative.
Source: https://www.indiatoday.in/amp/health/story/wegovy-announces-mega-price-cut-in-india-2817746-2025-11-11